Effective 1 December 2010 or as contracts allow, Lonza Microbial Control Europe adjusts prices of the following products : BarquatTM, LonzabacTM and AcrawaxTM C.
Price increases will be up to 15%. The increases are a result of increased raw material costs such as Palm Kernel Oil, mid-cut alcohol and tallow.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharma-ceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based re-search, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, the company had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.
For further information:
Business Unit Microbial Control
Tel. +41 61 316-8886
Fax +41 61 316-9886
Tel +41 61 316 8798
Fax +41 61 316 9798